Sankala Group
RPRX icon

Sankala Group’s Royalty Pharma RPRX Stock Holding History

Sankala Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$11.5K Hold
197
– – 0.01% 364
2026
Q2 		$11.8K Hold
197
– – 0.01% 375
2026
Q1 		$9.3K Hold
197
– – 0.01% 391
2025
Q4 		$9.1K Buy
+197
New +$7.51K 0.01% 399

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $127B AUM 33.25% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Sankala Group's RPRX Position: Q3 2026 in Review

Sankala Group held its Royalty Pharma (RPRX) position steady in Q3 2026 at 197 shares worth $11.5K. The position accounts for 0.01% of the portfolio, ranked #364.

Sankala Group first reported a position in RPRX in Q4 2025 and has held it in 4 quarters since. The position peaked at $11.8K in Q2 2026. 393 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • Sankala Group held 197 shares of Royalty Pharma worth $11.5K as of Q3 2026.
  • Sankala Group left its Royalty Pharma share count unchanged in Q3 2026.
  • Royalty Pharma made up 0.01% of Sankala Group's portfolio in Q3 2026, its #364 holding.
  • Sankala Group first reported a position in Royalty Pharma in Q4 2025 and has held it in 4 quarters since.
  • Sankala Group's Royalty Pharma position peaked at $11.8K in Q2 2026.
  • 393 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Sankala Group's 13F filing for Q3 2026, filed 9 Nov 2026.